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The design and synthesis of nucleoside analogues has been a 
subject of great interest in the discovery of novel anticancer and 
antiviral agents owing to the fact that they can be involved in the 
disruption of nucleic acid biosynthesis and thus inhibit cellular 
division and viral replication.[1] Additionally, they have been 
utilised for various gene silencing techniques as constituents of 
antisense oligonucleotides, small interfering RNAs (siRNAs) and 
microRNA-targeting oligonucleotides (anti-miRNAs).[2] 
In particular, conformationally restricted nucleosides such as  
“locked nucleic acids” (LNAs), whereby the sugar moiety of the 
nucleoside is locked in the bioactive C3’-endo (North) or C2’-
endo (South) conformations, represent an interesting class of 
nucleoside inhibitor as they can show a dramatic improvement in 
enzymatic recognition, as well as enhancing base stacking and 
backbone pre-organization.[3] Most of these systems are locked by 
virtue of bridging groups on the furanose unit alone, but there are 
also examples whereby the nucleobase is directly involved in the 
conformational restriction of the nucleoside (so-called 
‘cyclonucleosides’).[4] In this respect, we have an interest in the 
synthesis and use of anomeric spironucleosides, whereby the 
anomeric carbon belongs to both the sugar moiety and the 
nucleobase (Figure 1). This fixes the nucleobase in a specific 
orientation around the N-glycosidic bond, imposing an altered 
flexibility on the sugar moiety. Spiro-functionalised nucleosides 
have gained considerable interest with the discovery of (+)-
hydantocidin 1, a natural spironucleoside with potent herbicidal 
and plant growth regulatory activity.[5] However, to the best of our 
knowledge, synthetic work in this field is limited, with the 
majority of anomeric spirocycles being hydantoines or 
diketopiperazines analogues, or simple pseudonucleosides with 
anchored purinic and pyrimidinic bases.[6] 
As part of an on-going programme within our laboratories on the 
synthesis of non-natural nucleic acids,[7] we aimed to prepare a 
library of spiro-fuctionalised nucleosides, containing a [1,2,3]-
triazolyl moiety using a straightforward and highly stereoselective 
route. It was felt that this class of spironucleoside would make an 
interesting alternative to the [1,2,4]-triazolyl class of nucleoside 
whose biological activity is well known, owing to their 
resemblance to ribavirin 2.[8] We therefore evaluated our resulting 
[1,2,3]-triazolospironucleosides for their anti-HMV activity in 
vitro. 
Figure 1. Representation of a spironucleoside (where the shared carbon is at the 
anomeric position), the spironucleoside hydantocidin, and the triazolyl antiviral 
ribavirin.  
Results and Discussion 
As depicted in the retrosynthetic path (Scheme 1), the versatility 
of the synthetic strategy towards novel anomeric spironucleosides 
3 lies in the strategic installation of azide and alkyne moieties on 
the D-psicofuranose derivative 4, followed by an intramolecular 
Huisgen 1,3-dipolar cycloaddition to generate the spirocyclic 
[1,2,3]-triazolooxazine ring.[9] 
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Abstract: An efficient synthesis of spirocyclic triazolooxazine 
nucleosides is described. This was achieved by the conversion 
of -D-psicofuranose to the corresponding azido-derivative, 
followed by alkylation of the primary alcohol with a range of 
propargyl bromides - obtained via Sonogashira chemistry. The 
products of these reactions underwent 1,3-dipolar addition 
smoothly to generate the protected spirocyclic adducts. These 
were easily deprotected to give the corresponding ribose 
nucleosides. The library of compounds obtained was 
investigated for its antiviral activity, using MHV (Mouse 
Hepatitis Virus) as a model wherein derivative 3f showed the 
most promising activity and tolerability.  
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Scheme 1. Retrosynthetic access to [1,2,3]-spirotriazolooxazines 
The first part of the synthesis is shown in Scheme 2 and followed 
the general procedure described by Fuentes and co-workers.[10] 
This involved isomerisation of 1,2:4,5-di-O-isopropylidene-D-
psicopyranose 7 (easily prepared in a multigram scale using a 
straightforward three-step procedure from -D-fructopyranose[11]) 
to its furanose form 6a using amberlyst acid resin in acetone. The 
remaining alcohol was then converted to the benzoate ester 6b 
with a satisfactory overall yield of 70%. 
 
Scheme 2. Synthesis of the azido-ribose system. 
The benzoate ester was then treated with azidotrimethylsilane in 
the presence of trimethylsilyl triflate in acetonitrile under 
stringently anhydrous conditions at 0°C for 5 min to provide the 
-azido-1-trimethylsilyl ether 8 as the sole anomer. The silyl 
group was then removed smoothly with a mixture of acetone, 
acetic acid and methanol, giving alcohol 5a in 98% yield. 
The alkylation of alcohol 5a with a range of propargyl bromides  
was then undertaken using BEMP (2-tert-Butylimino-2-
diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine) as 
base to give the crude propargylic ether intermediates. The 3-
arylprop-2-ynyl partners for the O-alkylation were prepared from 
commercially available aryl iodides and propargyl alcohol using a 
two-step process involving Sonogashira coupling[12] followed by 
conversion of the resulting 3-arylprop-2-ynyl alcohols to their 
corresponding bromides under Appel conditions (see supporting 
information). The crude propargyl ether intermediates 9 then 
underwent efficient intramolecular 1,3-dipolar cycloaddition upon 
heating in toluene for 24h to give the novel protected anomeric 
spironucleoside library 10 (Table 1).[13] 
 
 
Table 1. Alkylation and 1,3-dipolar cycloaddition to access the spirocyclic 
nucleoside system. 
 
Entry Product R Overall yield, %[a] 
1 10a H 51 
2 10b Me 53 
3 10c Et 43 
4 10d 2-Napthyl 59 
5 10e Ph 44 
6 10f 4-Cl-C6H4 45 
7 10g 4-MeO-C6H4 43 
8 10h 4-F-C6H4 43 
9 10i 3-F-C6H4 39 
10 10j 2-F-C6H4 45 
11 10k n-Pentyl 36 
[a] Overall isolated yield for alkylation and cycloaddition. 
Finally, deacylation of the spiroderivative 10, using a 7 N solution 
of ammonia in methanol, followed by hydrolysis of the 
isopropylidene group with acidic resin (Dowex® 50W) gave 
straightforward access to anomeric spironucleosides 3 in good 
yield (Scheme 3). 
 
Scheme 3. Final deprotection steps to obtain novel anomeric spirocyclic system 3.  
As proof of final structure and to gain an understanding of the 
conformation of these systems, an X-ray crystal structure of 3g 
was obtained from a thin (0.02 x 0.03 x 0.31 mm) single-
crystal.  The structure in space group P21 has two independent 
molecules in the asymmetric unit, each having a disordered 
benzene ring occupying two distinct conformations (A and B) at 
ca. 60° different rotations about the aryl bond.  In the upper 
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molecule, conformation A is 92% occupied and B is 8% occupied, 
whilst in the lower molecule, the occupancies are reversed. 
 
Figure 2. Crystal structure of spirocyclic nucleoside 3g. CCDC no: 1003449, 
http://www.ccdc.cam.ac.uk 
Encouragingly, and considering the ‘locked’ nature of our 
nucleoside system, the crystal structure when overlaid with the 
[1,2,4]-triazolyl drug ribavirin showed remarkable similarities in 
conformation, particularly with respect to the ribose ring system 
(Figure 3). This prompted us to evaluate the antiviral activity of 
our nucleoside analogues and these studies are described below. 
 
Figure 3. Overlay of 3g (green) with ribavirin (red), showing the similarities in 
conformation. 
Biological Evaluation 
Coronaviruses are the largest and most complex RNA viruses 
known, encoding an unusually wide array of proteins that interact 
with or modify viral RNA.[14] Examples include Severe Acute 
Respiratory Syndrome (Sars), and Middle Eastern Respiratory 
Syndrome (Mers), which are amongst the most lethal viruses 
currently known.  Coronaviruses are predicted to be sensitive to 
RNA-like drugs,[15] and some nucleosides, such as ribavirin, have 
anti-coronaviral activity.[16,17] We therefore chose the model 
coronavirus Mouse hepatitis virus (MHV) as a proving ground for 
the novel nucleoside analogs described in this study for antiviral 
activity. 
In order to test for antiviral effects, MHV was grown on cells that 
had been pre-treated with the experimental compounds at a 
concentration of 1 mM.  The amount of MHV released from 
infected cells usually peaks at about 14 hours after infection.  Two 
of the treatments, 3b and 3f reduced the amount of MHV that was 
released by about ten-fold (Fig. 4A).   
 
Figure 4. Antiviral effects of novel nucleosides. (A) Cells were pre-treated with 1 
mM compounds, DMSO-containing vehicle or mock treated 3 hours before infection.  
Virus growth is shown relative to untreated controls. Compounds that reduced virus 
growth significantly (P<0.5 after unpaired t-test with Bonferroni correction) are 
indicated with stars. (B) Reduction of cytopathic effects by 3f.  Infected cells were 
fixed, stained with crystal violet and adherent cells were imaged by light microscopy.  
The number of nuclei in single cell bodies and in virus-induced multinucleate 
syncytia was normalized to the number of nuclei present in uninfected, untreated 
controls (Uninfected). (C) Experimental compounds were applied 3 hours before 
addition of the virus, and were maintained throughout the experiment.  Data points 
show the average virus titer ± standard deviation based on 5-8 replicates.  Virus 
growth was measured by plaque assay 14 hours after inoculation.  
MHV infection in 17Cl-1 cells normally results in formation of 
large multinucleate syncytia followed by detachment of cells from 
the culture flask.[18]  The most effective experimental compound 
from the previous assay was screened for the ability to protect 
cells from MHV-induced cytopathology.  17Cl-1 cells were pre-
treated with 3f 3 hours before infection, and surviving cells were 
photographed 24 hours after infection.  Treatment with 3f resulted 
in a dose-dependent reduction in both syncytium formation and 
detachment (Fig. 4B).  From these data it was concluded that 3f 
exerted a protective effect on treated cells at concentrations up to 
2 mM.  This also demonstrated that the apparent antiviral activity 
of 3f was not simply an artifact of cytotoxicity. 
More detailed dose-response experiments were performed for four 
of the experimental compounds in order to better gauge their 
antiviral potential.  Pretreatment with 2 mM of 3f produced the 
strongest antiviral effects, resulting in approximately one million-
fold reduction of MHV growth (Fig. 4C).  Together, these results 
demonstrate that 3f had antiviral activity against the model 
coronavirus MHV. 
The 17Cl-1 mouse lung fibroblast line supports high-titre MHV 
growth, and was therefore chosen for both toxicity and antiviral 
testing.  The effects of treatment on cell viability were assessed by 
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MTT assay.[19] Cell viability was assessed after one day or three 
days.  Of the compounds studied, the most promising were tested 
in this assay. 3d was the most cytotoxic, while 3b, 3f and 3k 
(included as a control) were better tolerated (Figure 5).  
 
Figure 5.  Dose-response effect of experimental compounds on cell viability. Effect 
of short (24h) and long (72h) exposure to experimental compounds on cell viability.  
Experiments were performed in a mouse lung 17Cl-1 fibroblast cell line that is 
highly permissive for MHV.  Relative viability as measured by conversion of 
formazan to MTT is plotted against treatment dose for four representative 
compounds 
The concentration which produced a 50% reduction in cell 
viability in these assays was greater than 1 mM for each of the 
experimental compounds tested (Table 2), demonstrating that the 
compounds are relatively non-toxic. 
Table 2. Relative activity of spirocyclic nucleosides 3b, 3d, 3f and 3k. 
Entry Nucleoside EC50 (µM) CC50 (µM) Therapeutic 
Index 
1 3b 410 ± 50 1510 ± 90 3.7 
2 3d > 2000 1170 ± 180 < 0.6 
3 3f 36 ± 13 > 2000 > 56 
4 3k 1290 ± 110 > 2000 > 1.6 
A further experiment was performed in order to learn more about 
the mechanism of 3f antiviral activity by evolving drug resistance.  
MHV was serially passaged eight times on 17Cl-1 cells, which 
had been pre-treated with 1 mM 3f, a concentration that 
reproducibly reduced viral growth by about 90%.  Previous work 
on antiviral compounds suggested that these conditions were 
appropriate for the selection of drug-resistant coronavirus within 
about five passages.[20] However, MHV grown in the presence of 
3f consistently produced about 10% of the virus produced in 
untreated control cells, and did not develop resistance (data not 
shown). These results suggest that the mechanism of action of 3f 
is unclear, and that effects of 3f on the cell cannot be ruled out as 
a potential explanation of the antiviral effects. 
In conclusion, a novel triazolospirocylcic nucleoside array was 
assembled efficiently through intramolecular 1,3-dipolar 
cycloaddition methodology, and allowed the identification of 
agents that showed promising antiviral activity towards MHV - 
the most promising of these being the 4-chlorophenyl derivative 
3f. Further work is underway to establish the mechanism of action 
of this inhibitor. 
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